# Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches

> **NCT01035983** · PHASE3 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 550 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Frovatriptan 2.5 mg

## Key facts

- **NCT ID:** NCT01035983
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 550 (ACTUAL)
- **Last updated:** 2024-01-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01035983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01035983, "Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01035983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*